Longeveron Inc - LGVNR STOCK NEWS

IMPACT

SENTIMENT

10/13/2023 04:05 PM

LGVN : Nasdaq LGVNR : Nasdaq

Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

IMPACT

SENTIMENT

10/12/2023 08:00 AM

LGVN : Nasdaq LGVNR : Nasdaq

Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

IMPACT

SENTIMENT

10/05/2023 07:00 AM

LGVN : Nasdaq LGVNR : Nasdaq

Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease

IMPACT

SENTIMENT

09/11/2023 08:00 AM

LGVN : Nasdaq LGVNR : Nasdaq

Longeveron Issues Letter to Stockholders

IMPACT

SENTIMENT

09/07/2023 08:00 AM

LGVN : Nasdaq LGVNR : Nasdaq

Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association

IMPACT

SENTIMENT

09/05/2023 08:00 AM

LGVN : Nasdaq LGVNR : Nasdaq

Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference

IMPACT

SENTIMENT

08/29/2023 08:00 AM

LGVN : Nasdaq LGVNR : Nasdaq

Longeveron to Participate in the 149th Annual National Investment Banking Association Conference

Longeveron Inc

Nasdaq:LGVNR

LGVNR Stock Data

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

About LGVNR

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome